Canada markets closed

Zymeworks Inc. (ZYME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.20+0.20 (+2.22%)
At close: 04:00PM EDT
9.20 0.00 (0.00%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.00
Open8.53
Bid9.18 x 100
Ask9.24 x 100
Day's Range8.53 - 9.24
52 Week Range6.01 - 13.14
Volume528,709
Avg. Volume590,088
Market Cap650.485M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

    Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in

  • GlobeNewswire

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference: Zymeworks’ management will participate in one-on-one meetings on May 15th in Las

  • GlobeNewswire

    Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

    VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results a